Kras G12Di
3 abstracts
Abstract
Effect of targeting FAK by ifebemtinib and immunogenic cell death of Kras G12C/G12D inhibition on the efficacy of PD1 blockade.Org: InxMed (Shanghai) Co., Ltd, Shanghai, China,
Abstract
Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer.Org: Caris Life Sciences, Irving, TX, West Virginia University Health Sciences Center Department of Epidemiology and Biostatistics, Mayo Clinic, Penn State Milton S. Hershey Medical Center, Hershey, PA,
Abstract
The clinical and genomic characteristics of KRAS G12D mutated cancers.Org: Shanghai OrigiMed Co., Ltd., Shanghai, China,